Christopher Squire

Dr. Christopher Squire


Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2003 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
GCGeorge R. Clark
George R. Clark
PPPatrycja D. Pytel
Patrycja D. Pytel
CSChristopher Squire
Christopher Squire
SNStephen Neidle
Stephen Neidle

1 December 2015 in Journal of Structural Biology
Verified
Journal Article
Closed access
YYYuliana Yosaatmadja
Yuliana Yosaatmadja
SSShevan Silva
Shevan Silva
JDJames M. Dickson
James M. Dickson
APAdam Patterson
Adam Patterson
JSJeff B. Smaill
Jeff B. Smaill
CSChristopher Squire
Christopher Squire

24 May 2004 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
NKNayden Koon
Nayden Koon
CSChristopher Squire
Christopher Squire
EBEdward N. Baker
Edward N. Baker
The leucine biosynthetic pathway is essential for the growth of Mycobacterium tuberculosis and is a potential target for the design of new anti-tuberculosis drugs. The crystal structure of α-isopropylmalate synthase, which catalyzes the first committed step in this pathway, has been determined by multiwavelength anomalous dispersion methods and refined at 2.0-Å resolution in complex with its substrate α-ketoisovalerate. The structure reveals a tightly associated, domain-swapped dimer in which each monomer comprises an (α/β) 8 TIM barrel catalytic domain, a helical linker domain, and a regulatory domain of novel fold. Mutational and crystallographic data indicate the latter as the site for leucine feedback inhibition of activity. Domain swapping enables the linker domain of one monomer to sit over the catalytic domain of the other, inserting residues into the active site that may be important in catalysis. The α-ketoisovalerate substrate binds to an active site zinc ion, adjacent to a cavity that can accommodate acetyl-CoA. Sequence and structural similarities point to a catalytic mechanism similar to that of malate synthase and an evolutionary relationship with an aldolase that catalyzes the reverse reaction on a similar substrate.


1 April 2005 in Structure
Verified
Journal Article
Closed access
CSChristopher Squire
Christopher Squire
JDJames M. Dickson
James M. Dickson
IIIvan Ivanovic
Ivan Ivanovic
EBEdward N. Baker
Edward N. Baker

1 June 2008 in Journal of Biological Chemistry
Verified
Journal Article
Open access
GBGhader Bashiri
Ghader Bashiri
CSChristopher Squire
Christopher Squire
NMNicole Moreland
Nicole Moreland
EBEdward N. Baker
Edward N. Baker
The modified flavin coenzyme F(420) is found in a restricted number of microorganisms. It is widely distributed in mycobacteria, however, where it is important in energy metabolism, and in Mycobacterium tuberculosis (Mtb) is implicated in redox processes related to non-replicating persistence. In Mtb, the F(420)-dependent glucose-6-phosphate dehydrogenase FGD1 provides reduced F(420) for the in vivo activation of the nitroimidazopyran prodrug PA-824, currently being developed for anti-tuberculosis therapy against both replicating and persistent bacteria. The structure of M. tuberculosis FGD1 has been determined by x-ray crystallography both in its apo state and in complex with F(420) and citrate at resolutions of 1.90 and 1.95 A(,) respectively. The structure reveals a highly specific F(420) binding mode, which is shared with several other F(420)-dependent enzymes. Citrate occupies the substrate binding pocket adjacent to F(420) and is shown to be a competitive inhibitor (IC(50) 43 microm). Modeling of the binding of the glucose 6-phosphate (G6P) substrate identifies a positively charged phosphate binding pocket and shows that G6P, like citrate, packs against the isoalloxazine moiety of F(420) and helps promote a butterfly bend conformation that facilitates F(420) reduction and catalysis.